Cardiac immune-related adverse events (irAEs) associated with anti-programmed death-1 (anti-PD1) immune checkpoint inhibitors (ICIs) are of major concern, as they can be fatal; however, their underlyi
Immune checkpoint inhibitors (ICIs)-associated cardiotoxic events (CEs) are of increasing concern. Existing research about glucocorticoids (GCs) on immunotherapy focused on ICIs’ efficacy and patients
C57BL6/J mice were treated with anti-PD-1 for 2 or 4 weeks, or with isotype control antibody. In echocardiography, cardiac dysfunction was seen both after 2 and 4 weeks, with decreased ejection fracti
